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ABSTRACT 
 
OBJECTIVE: Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk 
factors for diabetes, cardiovascular disease (CVD) and kidney disease. We determined the effects 
of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in people 
with IGT and/or IFG in the Diabetes REduction Assessment with ramipril and rosiglitazone 
Medication (DREAM) study. 
 
RESEARCH DESIGN AND METHODS: 5269 people aged ≥ 30 years, with IGT and/or IFG 
without known CVD or renal insufficiency were randomized to ramipril 15 mg/day vs. placebo, 
and rosiglitazone 8 mg/day vs. placebo. A composite cardio-renal outcome and its CVD and 
renal components were assessed during the 3-year follow-up. 
 
RESULTS: Compared to placebo, neither ramipril [15.7%, (412/2623) vs. 16.0%, (424/2646)] 
[Hazard ratio (HR) 0.98 (95% CI, 0.84 - 1.13) P = 0.75], nor rosiglitazone [15.0% (394/2635) vs. 
16.8% (442/2634)] [HR 0.87 (CI, 0.75 - 1.01) P = 0.07] reduced the risk of the cardio-renal 
composite outcome. Ramipril had no impact on the CVD and renal components. Rosiglitazone 
increased heart failure [0.53 vs. 0.08%, HR 7.04 (CI, 1.60 - 31.0) P = 0.01] but reduced the risk 
of the renal component [HR 0.80 (CI, 0.68 - 0.93) P = 0.005]; prevention of diabetes was 
independently associated with prevention of the renal component (P < 0.001).  
 
CONCLUSIONS: Ramipril did not alter the cardio-renal outcome or its components. 
Rosiglitazone, which reduced diabetes, also reduced the development of renal disease but not the 
cardio-renal outcome and increased the risk of heart failure. 
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he Diabetes REduction Assessment 
with ramipril and rosiglitazone 
Medication (DREAM) trial randomly 
allocated people with impaired fasting 
glucose (IFG) and/or impaired glucose 
tolerance (IGT) without known 
cardiovascular disease (CVD) or significant 
renal disease, to the angiotensin converting 
enzyme (ACE) inhibitor ramipril or placebo, 
and the thiazolidinedione rosiglitazone or 
placebo according to a 2 X 2 factorial design 
(1). After a median 3-year follow-up, ramipril 
did not significantly reduce the primary 
outcome of diabetes or death compared to 
placebo; however, it modestly reduced post-
load glucose levels and increased regression 
of IGT or IFG to normoglycemia (2). During 
the same period, rosiglitazone reduced the 
primary outcome by 60%, decreased fasting 
and post-load glucose levels, and increased 
regression to normoglycemia (3). Neither 
medication affected CVD events overall; 
however, 0.5% of participants allocated to 
rosiglitazone vs. 0.1% of those allocated to 
placebo developed congestive heart failure. 
IFG and IGT are both risk factors for 
CVD (4, 5); however people with IFG or IGT 
with CVD were excluded from this trial 
because of the known cardiovascular benefits 
of ACE inhibitors (6). As such, few CVD 
events were expected to accrue and the 
protocol pre-specified a composite “cardio-
renal” secondary outcome comprising either 
cardiovascular (CV) or renal events. The 
effects of ramipril and rosiglitazone on this 
composite outcome and its components are 
described herein. 
 
RESEARCH DESIGN AND METHODS 
The DREAM trial design has been 
reported previously (1 - 3). Briefly, 
nondiabetic men and women aged 30 or over 
with IFG [fasting plasma glucose between 
110 and 126 mg/dL (6.1-7.0 mmol/L)] and/or 
IGT [2-hour post 75 g oral load with plasma 
glucose between 140 and 200 mg/dL (7.8–
11.0 mmol/L)] were recruited from 191 
centers between July 2001 and August 2003. 
Key exclusion criteria were: known left 
ventricular ejection < 40% or congestive heart 
failure; documented CVD defined as ischemic 
heart disease, stroke, intermittent claudication 
with an ankle/arm pressure index of 0.8 or 
less, uncontrolled hypertension requiring 
ACE inhibitors or angiotensin-2 receptor 
blockers; known renal artery stenosis; known 
creatinine clearance < 0.6 ml/s, a serum 
creatinine ≥ 2.26 mg/dL (200 µmol/L), or 
clinical proteinuria. The protocol was 
approved by each center’s ethics committee 
and all participants provided written informed 
consent. 
Evaluation, randomization and follow-up. At 
baseline, participants were briefly examined 
and answered a standardized questionnaire 
regarding their medical history, current CVD 
symptoms, medication use, cardiovascular 
and renal therapies. After randomization 
participants were allocated to either ramipril 5 
mg/day for 2 months, 10 mg/day for 10 
months and subsequently 15 mg/day, or 
matching placebo, or either rosiglitazone 4 
mg/day for 2 months and 8 mg/day thereafter, 
or matching placebo. Study visits occurred at 
2 months, 6 months and every 6 months 
subsequently. The median follow-up period 
was 3 years.  
Clinical events were ascertained at each 
visit. Supine resting blood pressure and heart 
rate were measured at baseline, 2 months, 12 
months and every 12 months thereafter; 
electrocardiograms (ECGs) were recorded at 
baseline, 2 years and study end.  A serum and 
first morning urine sample were taken at 
baseline and study end and sent to the central 
laboratory for measurement of serum 
creatinine and a urinary albumin/creatinine 
ratio. Estimated glomerular filtration rate 
(eGFR) was calculated according to Cockroft 
T 
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and Gault based on the participant’s serum 
creatinine, age, gender and weight.  
Urine and serum creatinine were 
measured with a Roche® Hitachi 917 
analyzer and urine albumin was measured by 
a Federal Drug Administration approved size 
exclusion high performance liquid 
chromatography (HPLC) method. As the 
HPLC method detects greater amount of 
albumin in the urine than the immunoassay 
and is less likely to underestimate albumin 
fragments in people with diabetes (7, 8), 
albumin/creatinine ratio thresholds for 
microalbuminuria and clinical proteinuria that 
corresponded to immunoassay thresholds of 
2.0 and 36 mg/mmol respectively 
(prespecified in the DREAM protocol) were 
identified by comparing HPLC and 
immunoassay analysis of urine from the Heart 
Outcome Prevention Evaluation (HOPE) (9 -
11) 
 
STUDY OUTCOMES 
The pre-specified composite cardio-renal 
outcome included either: a) a composite CV 
outcome defined as the first occurrence of any 
CV death, successful cardiac resuscitation, 
non-fatal myocardial infarction (MI), stroke, 
revascularization procedure, new stable or 
unstable angina with documented ischemia, or 
heart failure; or b) a composite renal outcome 
defined as any of: i) progression from 
normoalbuminuria to either microalbuminuria 
or proteinuria, or from microalbuminuria to 
proteinuria; ii) a decrease in eGFR of 30% or 
more; or iii) renal insufficiency requiring 
dialysis or transplantation. Microalbuminuria 
was defined as a single first morning 
albumin/creatinine ratio > 4.4 mg/mmol and < 
36 mg/mmol. Clinical proteinuria was defined 
as either an albumin/creatinine ratio > 36 
mg/mmol or an adjudicated report of clinical 
proteinuria.  Regression from 
microalbuminuria to normoalbuminuria was 
also assessed.   
CV death included sudden CV death, 
death due to MI, stroke, heart failure, 
arrhythmia, vascular disease (pulmonary 
embolism, aortic rupture), presumed CVD 
(death not fulfilling all criteria for MI or 
stroke) or death of unknown cause.  The 
diagnosis of MI required: a) a troponin level 
that was >  twice the lower level signifying  
necrosis or a creatine kinase MB level that 
was > 1.5 times the upper normal limit or 
other cardiac enzymes > twice the upper 
normal limit; and b) either acute ischemic 
ECG  changes or ischemic chest pain lasting 
at least 10 minutes. The diagnosis of stroke 
required an acute localized neurological 
deficit lasting at least 24 hours and imaging 
for its etiologic type. Heart failure required 
hospitalization or an emergency stay during 
two consecutive calendar days due to heart 
failure with 2 of the 3 following criteria: a) 
signs and/or symptoms of heart failure, b) 
radiological evidence of pulmonary 
congestion or c) use of diuretics or inotropes 
or vasodilator agents. All events were 
adjudicated by cardiologists and 
endocrinologists blinded to the study 
medications, including 3 new CVD cases of 
angina (one on rosiglitazone alone, one on 
ramipril alone and one on double placebo) 
that were not listed in the original DREAM 
publications as they occurred during the 
active phase but were only identified during 
the final close-out of the clinical sites 
following the post-trial washout phase. 
 
STATISTICAL ANALYSIS 
Student’s t test and chi square tests were 
used for univariate comparisons of continuous 
and categorical variables respectively. 
Participants without urine and serum sample 
at the end of the study were considered to 
have values that did not differ from baseline. 
Individuals for whom CVD status was 
unavailable at the final visit were censored at 
the time of their last visit. Cox proportional 
hazards models were used to estimate the 
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effect of each of the study drugs stratified for 
the other drug, on the hazard ratios (HR) of 
CVD outcomes and the possibility of 
statistical interaction between the two study 
drugs on these outcomes was assessed by 
including an interaction term in the model. 
HR and 95% confidence intervals (CI) were 
calculated with corresponding two-sided P 
values. The HRs for cardio-renal and renal 
outcomes were calculated using logistic 
regression models adjusting for the effect of 
the other drug; Cox models for these 
outcomes could not be used as the cardio-
renal and renal outcomes were only assessed 
in all participants at the end of the study. 
Logistic regression models were also 
constructed to determine if prevention of 
diabetes with rosiglitazone may have also 
prevented the composite renal outcome (the 
dependent variable). In the first model, 
incident diabetes (during the DREAM median 
follow-up period of 3 years) and rosiglitazone 
allocation were included as independent 
variables. In the second model, diabetes was 
replaced by time of diabetes development, 
classified as either occurring in the first 1.5 
years of follow-up, after 1.5 years, or never. 
Ramipril allocation, baseline 
albumin/creatinine ratio and baseline 
calculated eGFR were also included as 
independent variables in these 2 models.  
Interactions were tested by including an 
interaction term in the model.   
 
RESULTS 
CVD status at trial end was available for 
98% of randomized participants. A final visit 
urine albumin/creatinine value and a serum 
creatinine value were available for 4106 
(78%) and 4236 (80%) participants 
respectively. In comparison to the participants 
who had a final renal ascertainment, those 
who did not were younger (53.5 vs. 55.0 
years, P = 0.0013), more likely to be women 
(62.1 vs. 58.6%,  P = 0.042), had a lower 
fasting plasma glucose (5.78 vs. 5.85 mmol/L, 
P = 0.004),  a higher 2-hour glucose level 
(8.80 vs. 8.66 mmol/L,  P = 0.006), a lower 
serum creatinine (74.3 vs. 75.7 mg/dL, P = 
0.04), were more likely to be smokers  (14.8 
vs. 11.6%,  P = 0.004), took less aspirin (12.1 
vs 14.8%, P = 0.023) , and lipid lowering 
agents (12.5 vs. 15.4%, P = 0.020).   
Cardio-renal outcome. During the 3-year 
follow-up, 836 participants had a first 
occurrence of the composite cardio-renal 
outcome, comprising 133 (2.5%) CV 
composite outcomes and 718 (13.6%) renal 
composite outcomes. The composite cardio-
renal outcome occurred in a) 412/2623 
(15.7%) participants allocated to ramipril and 
424/2646 (16.0%) allocated to placebo [HR 
0.98 (95% CI, 0.84 - 1.13) P = 0.75] and b) 
394/2635 (15.0%) participants allocated to 
rosiglitazone and 442/2634 (16.8%) allocated 
to placebo [HR 0.87 (0.75 - 1.01) P = 0.07]. 
The baseline characteristics of the participants 
with and without cardio-renal events and their 
components are shown in Table 1. There was 
no statistically significant interaction between 
the effects of ramipril and rosiglitazone on the 
cardio-renal outcome (P = 0.09). Event rates 
by each cell of the factorial design were: a) 
15.6% (204/1310) for rosiglitazone and 
ramipril; b) 15.7% (207/1313) for ramipril 
and placebo; c) 14.3% (189/1325) for 
rosiglitazone and placebo; and d) 17.8% 
(235/1321) for placebo and placebo. 
Cardiovascular component. Ramipril did not 
alter the rate of CV events or the composite of 
CV death, non-fatal MI or stroke, or any 
individual CV event. Similarly, rosiglitazone 
did not reduce the overall risk of CV events 
but significantly increased the risk for heart 
failure (Table 2). There was no interaction for 
the CV component outcomes between 
ramipril and rosiglitazone (P = 0.07). Event 
rates by each cell of the factorial design were: 
a) 3.4% (45/1310) for rosiglitazone and 
ramipril; b) 1.8% (24/1313) for ramipril and 
placebo; c) 2.4% (32/1325) for rosiglitazone 
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and placebo; and d) 2.4% (32/1321) for 
placebo and placebo. 
The 16 patients who had heart failure 
were at greater risk for CV events than the 
other DREAM participants. They were older 
(67.5 vs. 54.7 years), had higher systolic 
blood pressure (147.5 vs. 136.1 mmHg), more 
often had a history of hypertension (94 vs. 
43%) and left ventricular hypertrophy on 
ECG tracing (25 vs. 5%).They were also 
taking more antiplatelets, diuretics, 
betablockers, angiotensin receptor blockers, 
lipid lowering agents and calcium channel 
blockers. Data extracted from the 
documentation provided for adjudication of 
the 16  participants with heart failure showed 
that a) 3 cases were associated with severe 
valvular heart disease, b) 4 with an acute 
coronary syndrome, c) 2 with a left 
ventricular ejection fraction < 40%, and d) 2 
with atrial fibrillation. Of the 14 participants 
who developed heart failure on rosiglitazone, 
medication was discontinued in 9, 2 died (one 
post–operatively following aortic valve 
replacement and coronary artery bypass graft 
surgery, and one death due to acute MI 
associated with the heart failure); one patient 
with renal failure had recurrent heart failure 
despite having discontinued rosiglitazone at 
the time of the first episode.  
Renal component. Ramipril did not alter the 
renal component of the composite outcome 
(Table 3). Rosiglitazone reduced this 
component by 20% due to a reduction in 
progression of albuminuria but the fall in 
eGFR by > 30% was not significant (Table 3). 
In a logistic model that also included 
rosiglitazone allocation, ramipril allocation, 
baseline albumin/creatinine ratio, and the 
baseline eGFR, the renal outcome was 
independently associated with both incident 
diabetes [HR 1.42 (1.16 - 1.74) P < 0.001] 
and allocation to rosiglitazone [HR 0.83 (0.70 
- 0.98) P = 0.027]; this HR remained 
unchanged when incident diabetes was 
replaced by mean fasting plasma glucose in 
the equation. This possible relationship 
between prevention of diabetes with 
rosiglitazone and prevention of the renal 
outcome was explored by replacing diabetes 
by time of diabetes development. After 
controlling for allocation to rosiglitazone and 
the other variables, developing diabetes 
within the first 1.5 years of follow-up was 
associated with a 1.59 fold higher risk of the 
renal outcome [(1.16 - 2.17) P = 0.0039] 
versus remaining free of diabetes; developing 
diabetes after 1.5 years was associated with a 
1.34 fold higher risk [(1.05 - 1.71)  P = 
0.0019]. There was no interaction for the 
renal component outcomes between ramipril 
and rosiglitazone (P = 0.2). Event rates by 
each cell of the factorial design were: a) 
12.7% (166/1310) for rosiglitazone and 
ramipril; b), 14.2% (186/1313) for ramipril 
and placebo; c) 11.8% (157/1325), for 
rosiglitazone and placebo; and d) 15.7% 
(208/1321) for placebo and placebo. 
 
CONCLUSIONS 
The DREAM trial excluded people with 
IFG and/or IGT who had CVD, because of the 
known benefits of ramipril on CVD. As such, 
when the trial was designed: a) it was 
recognized that there would be a low CVD 
event rate which would not provide sufficient 
power to detect even modest effects on CVD  
– an assumption confirmed by the low 2.5% 
CVD incidence; and b) a composite cardio-
renal secondary outcome that would yield a 
higher event rate was prespecified. Neither 
ramipril nor rosiglitazone significantly 
affected this cardio-renal composite outcome, 
and ramipril did not alter its CV or renal 
components. However, rosiglitazone 
significantly reduced the renal component of 
this outcome but increased the risk of heart 
failure. 
The fact that ramipril reduces CV 
outcomes and progression of albuminuria in 
people at high risk of CVD, has been clearly 
shown in the HOPE study (10,11). This effect 
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was attributed to the modulation of the renin-
angiotensin aldosterone system. The absence 
of such benefit in the DREAM trial may have 
been due to the low incidence of CVD [the 
composite of CV death, MI or stroke was 
documented in only 1% (56/5269) compared 
to 16% (1477/9297) in HOPE] and the 
relatively short follow-up of 3 years 
compared to 4.5 years in HOPE. Moreover, as 
the low-risk DREAM participants may have 
low activation of the renin-angiotensin 
system, further inhibition with ramipril would 
be expected to have a minimal effect.   
Diabetes is a strong risk factor for renal 
disease. As the glucose criteria used to 
diagnose diabetes mellitus represent 
thresholds above which the risk of retinal and 
renal disease rises rapidly, an intervention that 
reduces the incidence of diabetes (and 
therefore the rise of glucose levels past the 
diabetes thresholds) may also reduce renal 
disease. This possibility is strongly supported 
by these findings: rosiglitazone, which clearly 
reduced the risk of diabetes, also reduced the 
risk of renal disease by 20% versus placebo, 
with consistent changes of the renal outcome. 
It is also supported by the regression models 
in which incident diabetes, time of 
development of diabetes (before or after 1.5 
years), and rosiglitazone allocation were 
independently associated with the renal 
outcome. Whether additional effects beyond 
improved metabolic control contributed to the 
renal effects observed cannot be determined 
from the present findings. 
Rosiglitazone clearly increased the risk of 
heart failure. Such an effect has been 
repeatedly noted in other thiazolidinedione 
studies (12-16) and appears to be due to 
sodium and water retention at the renal 
collecting duct noted above, an increased 
plasma renin activity (17-19) perhaps related 
in part to a modest fall in blood pressure (20, 
21) and increased insulin action (20).Two 
echocardiographic studies showed that 
rosiglitazone did not significantly reduce left 
systolic ventricular function (22,23). Of note 
is the fact that the actual 0.5% incidence of 
heart failure with rosiglitazone during this 3-
year trial of people at low risk for CV 
outcomes, was lower than the 1.5% (12), 
1.7% (15) and 5.7% (16) incidence reported 
in similar length thiazolidinedione trials of 
people at higher risk of CV outcomes. 
Nevertheless, the high relative risk of heart 
failure represents new evidence that low risk 
people are not protected from this side effect. 
The lack of a clear cardio-renal benefit 
(due to no effect on the CV component of the 
composite) was surprising in light of the 
many favorable effects of rosiglitazone on 
surrogate markers of CVD (15, 20, 21, 24). It 
is possible that the short follow-up period and 
the low CV outcome incidence were 
insufficient to allow a modest CV effect to 
emerge. Alternatively, rosiglitazone may have 
a neutral effect on ischemic CVD events. 
Indeed, recent concerns that it may increase 
the risk of ischemic CVD (25) but the absence 
of any clear CV benefit or harm of 
rosiglitazone in an interim analysis of a large 
CV trial (15) have fueled uncertainty 
regarding its effects on ischemic CVD and 
highlight the need for large trials with 
sufficient power to resolve this dilemma.  
Strengths of our study include the fact that 
all of the measured outcomes were 
prospectively defined, collected and 
adjudicated. The findings are limited by the 
fact that renal outcomes were only available 
in 78% of participants at study end.    
In summary, the DREAM study showed 
no significant impact of ramipril on the 
composite cardio-renal outcome or its 
cardiovascular or renal components. It also 
did not show an effect of rosiglitazone on the 
cardio-renal outcome or its cardiovascular 
component but it increased heart failure. 
However, rosiglitazone did reduce the renal 
component of this outcome - one of the 
consequences of diabetes - in addition to 
reducing the incidence of diabetes itself.  
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TABLE 1.  Baseline characteristics of participants with and without cardio-renal, cardiovascular and renal outcomes 
Characteristic Cardio-renal Cardiovascular  Renal 
 Yes No Yes No Yes No 
Numbers 836 (100) 4433 (100) 133 (100) 5136 (100) 718 (100) 4551 (100) 
Age (years) 57.4 ± 11.2 54.2 ± 10.8a 62.9 ± 10.0 54.5 ±10.9a 56.4 ± 11.1 54.4 ± 10.9a 
Women 521 (62.3) 2599 (58.6)d 60 (45.1) 3060 (59.6)b 472 (65.7) 2648 (58.2)a 
Isolated IFG 110 (13.2) 629 (14.2) 17 (12.8) 722 (14.1) 95 (13.2) 644 (14.2) 
Isolated IGT 459 (54.9) 2568 (57.9) 62 (46.6) 2965 (57.7)c 408 (56.8) 2619 (57.6) 
IFG+IGT 267 (32.0) 1236 (27.9)d 54 (40.6) 1449 (28.2)c 215 (29.9) 1288 (28.3) 
Fasting blood sugar (mmol/L) 5.88 ± 0.67 5.82 ± 0.66d 6.01 ± 0.66 5.83 ± 0.66c 5.85 ± 0.67 5.83 ± 0.66 
2 h post 75 g glucose (mmol/L) 8.74 ± 1.43 8.67 ± 1.43 8.80 ± 1.49 8.68 ± 1.43 8.73 ± 1.43 8.68 ± 1.43 
Serum creatinine (mmol/L) 74.5 ± 22.2 75.6 ± 16.5 83.7 ± 20.5 75.3 ± 17.4 0 72.9 ± 22.0 75.9 ± 16.7b 
Microalbuminuria 96 (11.6) 895 (20.9) a 37 (29.1) 954 (19.1) c 62 (8.7) 929 (21.1) a 
Hypercholesterolemia 307 (36.7) 1564 (35.3) 64 (48.1) 1807 (35.2)c 249 (34.7) 1622 (35.6) 
History of hypertension 428 (51.2) 1863 (42.0)a 87 (65.4) 2204 (42.9)a 355 (49.4) 1936 (42.5)c 
Systolic blood pressure (mmHg) 138.4 ±17.9 135.7± 18.4b 142.2 ± 18.4 135.9 ±18.3a 137.7 ±17.6 135.8± 18.5d 
Diastolic blood pressure (mm/Hg) 83.4 ± 10.4 83.4 ± 10.9 84.1 ± 10.6 83.4 ± 10.8 83.3 ± 10.4 83.4 ± 10.8 
Ankle brachial index  1.21 ± 0.17 1.22 ±0.18 1.19 ± 0.20 1.19 ± 0.20 1.21 ± 0.16 1.22 ± 0.18 
Body mass index (kg/m2) 31±.0 5.7 30.9 ±5.6 30.5 ± 5.6 30.9 ± 5.6 31.0 ± 5.6 30.9 ± 5.6 
Waist-to hip ratio men 0.96± 0.06 0.96 ±0.07 0.97 ±0.06 0.96 ± 0.07 0.96 ± 0.06 0.96 ± 0.07 
Waist-to hip ratio women  0.87 ± 0.08 0.87± 0.08 0.88 ± 0.08 0.87 ± 0.08 0.87 ± 0.08 0.87 ± 0.08 
Current smokers 110 (13.2) 532 (12.0) 18 (13.5) 624 (12.2) 94 (13.1) 548 (12.0) 
Alanine aminotransferase U/L 27.2 ±14.6 29.2 ± 16.5c 26.9 ± 13.6 28.9 ± 16.3 27.2 ± 14.8 29.1 ± 16.5c 
ECG – LVH  with ST-T changes 25 (3.0) 51 (1.2)a 11 (8.3) 65 (1.3)a 18.0 (2.5) 58.0 (1.3)c 
Aspirin or antiplatelets 150 (18.0) 604 (13.6)b 33 (24.8) 721 (14.0)b 120 (16.7) 634 (13.9)d 
Thiazide 94 (11.3) 419 (9.5) 25 (18.8) 488 (9.5)b 72 (10.0) 441 (9.7) 
Other diuretics 71 (8.5) 203 (4.6)a 20 (15.0) 254 (5.0)a 52 (7.3) 222 (4.9)c 
Aldactone 10 (1.2) 30 (0.7) 4 (3.0) 36 (0.7)c 8 (1.1) 32 (0.7) 
Angiotensin receptor blockers 48 (5.7) 238 (5.4) 14 (10.5) 272 (5.3)c 36 (5.0) 250 (5.5) 
Beta blockers 174 (20.8) 738 (16.6)c 36 (27.1) 876 (17.1)c 143 (19.9) 769 (16.9)d 
Calcium channel blockers 152 (18.2) 525 (11.8)a 35 (26.3) 642 (12.5)a 122 (17.0) 555 (12.2)b 
Alpha blockers 18 (2.2) 90 (2.0) 3 (2.3) 105 (2.0) 15 (2.1) 93 (2.0) 
Lipid lowering agents 132 (15.8) 648 (14.6) 32 (24.1) 748 (14.6)c 102 (14.2) 678 (14.9) 
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Numbers in parentheses = %; a P< 0.0001; b P < 0.001;  c P < 0.01; d P < 0.05; IFG=impaired fasting glucose,  IGT=impaired glucose tolerance,  ECG= 
electrocardiographic, LVH=left ventricular hypertrophy; 
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TABLE  2.  Cardiovascular Component of the Cardio-renal Composite 
Event Ramipril Placebo HR (95% CI) Rosiglitazone Placebo HR (95% CI) 
 N (%) N (%)  N (%) N (%)  
CV composite 69 (2.6) 64 (2.4) 1.09 (0.78-1.53)a 77 (2.9) 56 (2.1) 1.38 (0.98-1.95)b 
        CV death 12 (0.5) 10 (0.4) 1.21 (0.52-2.80) 12 (0.5) 10 (0.4) 1.20 (0.52-2.77) 
        MI 14 (0.5) 11 (0.4) 1.29 (0.59-2.84) 16 (0.6) 9 (0.3) 1.78 (0.79-4.03) 
        Stroke 4 (0.2) 8 (0.3) 0.50 (0.15-1.66) 7 (0.3) 5 (0.2) 1.40 (0.44-4.40) 
        CHF 12 (0.5) 4 (0.2) 3.06 (0.99-9.48) 14 (0.5) 2 (0.1) 7.04 (1.60-31.0) 
        Revascularization 28 (1.1) 38 (1.4) 0.74 (0.46-1.21) 37 (1.4) 29 (1.1) 1.27 (0.78-2.07) 
        New angina 24 (0.9) 20 (0.8) 1.21 (0.67-2.19) 24 (0.9) 20 (0.8) 1.20 (0.66-2.17) 
CV death, MI or stroke 27 (1.0) 29 (1.1) 0.94 (0.56-1.59)a 33 (1.3) 23 (0.9) 1.43 (0.84-2.44)a 
Total mortality 31 (1.2) 32 (1.2) 0.98 (0.60-1.61)a 30 (1.1) 33 (1.3) 0.91 (0.56-1.49)a 
 CV-cardiovascular; MI-myocardial infarction; CHF-congestive heart failure; Revascularization - interventions on either coronary or peripheral arteries. 
The CV composite outcome represents the first occurrence of CV death, MI or stroke. For the other individual events, all participants with an event are 
included in each row. aP>0.1; bP=0.067 
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TABLE  3. Renal Component of the Cardio-renal Composite 
Event Ramipril Placebo HR (95% CI) Rosiglitazone Placebo HR (95% CI) 
 N (%) N (%)  N (%) N (%)  
Renal composite 353 (13.5) 365 (13.8) 0.97 (0.83-1.14)a 324 (12.3) 394 (15.0) 0.80 (0.68-0.93)c 
  Albuminuria Progression  267 (10.2) 287 (10.9) 0.93 (0.78-1.11)a 253 (9.6) 301 (11.4) 0.82 (0.69-0.98)d 
      Normal to MA 253 (9.7) 273 (10.3) 0.93 (0.77-1.11) 241 (9.2) 285 (10.8) 0.83 (0.69-0.99) 
      Normal to proteinuria 5 (0.19) 4 (0.15) 1.26 (0.34-4.71) 6 (0.23) 3 (0.11) 2.00 (0.50-8.01) 
      MA to proteinuria  9 (0.34) 10 (0.39) 0.91 (0.37-2.24) 6 (0.23) 13 (0.49) 0.46 (0.18-1.21) 
  Decreased eGFR ≥ 30% 99 (3.8) 88 (3.3) 1.14 (0.85-1.53)a 82 (3.1) 105 (4.0) 0.77 (0.58-1.04)e 
MA regression to normal 204 (53.7) 174 (47.3) 1.30 (0.98-1.74)b 193 (52.5) 185 (48.7) 1.18 (0.88-1.57)a 
eGFR-estimated glomerular filtration rate; MA-microalbuminuria. The renal component of the composite is the first occurrence of any of progression of albuminuria, 
decreased eGFR by ≥ 30% or renal insufficiency requiring dialysis or transplantation. For the other individual events, all participants with this event are included in each 
row. aP>0.1; bP=0.073 cP=0.005;dP=0.031;eP=0.087 
